NaturalAntibody, Al. Piastów 22, Szczecin, Poland.
Harvard Medical School, 240 Longwood Ave, Boston, MA, USA.
Nucleic Acids Res. 2022 Jan 7;50(D1):D1273-D1281. doi: 10.1093/nar/gkab1021.
Nanobodies, a subclass of antibodies found in camelids, are versatile molecular binding scaffolds composed of a single polypeptide chain. The small size of nanobodies bestows multiple therapeutic advantages (stability, tumor penetration) with the first therapeutic approval in 2018 cementing the clinical viability of this format. Structured data and sequence information of nanobodies will enable the accelerated clinical development of nanobody-based therapeutics. Though the nanobody sequence and structure data are deposited in the public domain at an accelerating pace, the heterogeneity of sources and lack of standardization hampers reliable harvesting of nanobody information. We address this issue by creating the Integrated Database of Nanobodies for Immunoinformatics (INDI, http://naturalantibody.com/nanobodies). INDI collates nanobodies from all the major public outlets of biological sequences: patents, GenBank, next-generation sequencing repositories, structures and scientific publications. We equip INDI with powerful nanobody-specific sequence and text search facilitating access to >11 million nanobody sequences. INDI should facilitate development of novel nanobody-specific computational protocols helping to deliver on the therapeutic promise of this drug format.
纳米抗体是骆驼科动物中发现的抗体的一个子类,是由单条多肽链组成的多功能分子结合支架。纳米抗体的小尺寸赋予了其多种治疗优势(稳定性、肿瘤穿透性),2018 年的首个治疗批准证实了这种形式的临床可行性。纳米抗体的结构化数据和序列信息将加速基于纳米抗体的治疗药物的临床开发。尽管纳米抗体序列和结构数据正在以加速的速度在公共领域中进行存储,但来源的异质性和缺乏标准化阻碍了可靠地获取纳米抗体信息。我们通过创建免疫信息学用纳米抗体综合数据库(INDI,http://naturalantibody.com/nanobodies)来解决这个问题。INDI 汇集了来自所有主要生物序列公共资源的纳米抗体:专利、GenBank、下一代测序存储库、结构和科学出版物。我们为 INDI 配备了强大的纳米抗体特异性序列和文本搜索功能,可访问超过 1100 万个纳米抗体序列。INDI 应该有助于开发新型的纳米抗体特异性计算协议,从而帮助实现这种药物形式的治疗承诺。